ORLANDO, Florida, April 2, 2017 /PRNewswire/ --
Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories. The results were presented today at the Endocrine Society's 99th Annual Meeting and Expo (ENDO 2017) in Orlando, FL, US.
"Type 2 diabetes is a complex disease, and as a result many patients are not reaching their targets on current oral antidiabetic therapy," said Vanita Aroda, SUSTAIN 4 investigator and physician investigator at the MedStar Health Research Institute, Hyattsville, MD, US. "Results from this post hoc analysis show that once-weekly semaglutide consistently lowered blood glucose and weight in people with type 2 diabetes regardless of their current oral antidiabetic therapy."
On a background of metformin or metformin plus sulfonylurea, treatment with semaglutide (0.5 mg/1.0 mg) significantly reduced HbA1c compared with all treatment comparators (p